Close Menu

NEW YORK – Interpace Biosciences reported Wednesday morning that its third quarter revenues rose 6 percent year over year.

For the three months ended Sept. 30, 2020 the Parsippany, New Jersey-based firm had total revenues of $8.2 million compared to $7.7 million a year ago, beating analysts' average expectations of $7.6 million.

Interpace also announced that it closed a $5 million bridge loan with existing equity investors Ampersand Capitol Partners and 1315 Capital Partners earlier this month. The firm concurrently terminated its credit facility with Silicon Valley Bank.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.